SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

ANG Lifesciences - Quaterly Results

14 Aug 2025 Evaluate
The turnover zoomed to Rs. 245.32 millions, up 51.65% for the June 2025 quarter as against Rs. 161.77 millions during the year-ago period.The Net Loss for the quarter ended June 2025 is Rs. -7.87 millions as compared to Net Loss of Rs. -27.66 millions of corresponding quarter ended June 2024 Operating profit Margin for the quarter ended June 2025 improved to 20.26% as compared to -5.69% of corresponding quarter ended June 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 245.32 161.77 51.65 245.32 161.77 51.65 899.10 1313.69 -31.56
Other Income 1.73 13.58 -87.26 1.73 13.58 -87.26 24.44 8.35 192.69
PBIDT 20.26 -5.69 -456.06 20.26 -5.69 -456.06 6.36 99.51 -93.61
Interest 16.06 16.69 -3.77 16.06 16.69 -3.77 73.04 93.28 -21.70
PBDT 4.20 -22.38 -118.77 4.20 -22.38 -118.77 -66.68 -11.12 499.64
Depreciation 14.46 15.11 -4.30 14.46 15.11 -4.30 62.70 77.55 -19.15
PBT -10.26 -37.49 -72.63 -10.26 -37.49 -72.63 -129.38 -88.67 45.91
TAX -2.39 -9.83 -75.69 -2.39 -9.83 -75.69 -25.94 -2.19 1084.47
Deferred Tax -2.39 -9.83 -75.69 -2.39 -9.83 -75.69 -25.94 -2.21 1073.76
PAT -7.87 -27.66 -71.55 -7.87 -27.66 -71.55 -103.44 -86.48 19.61
Equity 130.58 130.58 0.00 130.58 130.58 0.00 130.58 130.58 0.00
PBIDTM(%) 8.26 -3.52 -334.80 8.26 -3.52 -334.80 0.71 7.57 -90.66

ANG Lifesciences Share Price

26.10 -0.46 (-1.73%)
21-Apr-2026 13:23 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1674.00
Dr. Reddys Lab 1221.00
Cipla 1230.55
Zydus Lifesciences 930.45
Lupin 2323.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×